Provides molecular diagnostic testing services. Offers genetic testing for inherited conditions. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 24% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 1.8× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 77% of them.
Analysts' average target sits 7% below today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 81% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $322.7M a year. A small number, but proof the product has real buyers.
There is $336.1M in the vault; even if every debt were paid off, $328.4M would remain.
A loss of $60.5M against $322.7M in annual sales.
Over the last 12 months, executives reported 65 sells against just 20 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, FLGT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FLGT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.